St Jude Medical has announced that its mechanical heart valve technology has been utilised by more than two million patients since its introduction more than 30 years ago.
The company has hailed the milestone as a "landmark achievement" in the field of prosthetic heart valves, adding that it demonstrates the proven reliability and durability of the devices.
It comes a year after the manufacturer launched the latest addition to its heart valve range in Europe, the CE Mark-approved Trifecta system.
Frank Callaghan, president of the St Jude Medical cardiovascular division, hailed the role played by physicians and institutions in developing the products, as well as the trust they have subsequently placed in the technology.
"As we move forward with new technologies like our Trifecta valve, we are not only continuing the legacy that was instilled by our mechanical valves, but innovating advanced, best-in-class life-saving technologies," he added.
In January 2011, the company received European approval to manufacture medical device components at its new site in Malaysia, which will be used to create cardiac rhythm management systems.See all the latest jobs in Medical Devices